The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis

Journal of Veterinary Internal Medicine

Volumn 22, Issue 2, 2008, Pages 380-387

  Fan, Timothy M ^a   De Lorimier, L P ^a   Garrett, L D ^a   Lacoste, H I ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Aminobisphosphonate; Dual energy x ray absorptiometry; Pain alleviation; Primary and secondary bone neoplasm; Urine N telopeptide

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE; BONE DENSITY; COHORT ANALYSIS; COMPARATIVE STUDY; DOG; DOG DISEASE; DRUG EFFECT; FEMALE; MALE; NEOPLASM; OSTEOLYSIS; PROSPECTIVE STUDY;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; DOG DISEASES; DOGS; FEMALE; IMIDAZOLES; MALE; NEOPLASMS; OSTEOLYSIS; PROSPECTIVE STUDIES;

ANIMALIA; CANIS FAMILIARIS;

EID: 42449157667     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0046.x     Document Type: Article

References (34)

1. Clohisy DR, Mantyh PW. Bone cancer pain. Cancer 2003;97:866-873.
2. Veri A, D'Andrea MR, Bonginelli P, et al. Clinical usefulness of bisphosphonates in oncology: Treatment of bone metastases, antitumoral activity and effect on bone resorption markers. Int J Biol Markers 2007;22:24-33.
3. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.
4. Lipton A. Toward new horizons: The future of bisphosphonate therapy. Oncologist 2004;9(Suppl 4):38-47.
5. Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther 2005;5:817-832.
6. Caraglia M, Santini D, Marra M, et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006;13:7-26.
7. Ashton JA, Farese JP, Milner RJ, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res 2005;66:885-891.
8. Farese JP, Ashton J, Milner R, et al. The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro. In Vitro Cell Dev Biol Anim 2004;40:113-117.
9. Poirier VJ, Huelsmeyer MK, Kurzman ID, et al. The bisphosphonates alendronate and zoledronate are inhibitors of canine and human osteosarcoma cell growth in vitro. Vet Comp Oncology 2003;1:207-215.
10. Clamp A, Danson S, Nguyen H, et al. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 2004;5:607-616.
11. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97: 59-69.
12. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-4935.
13. Pectasides D, Nikolaou M, Farmakis D, et al. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res 2005;25:1457-1463.
14. Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev 2005;31(Suppl 3):1-8.
15. Fan TM, de Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19:74-80.
16. Fan TM, de Lorimier LP, O'Dell-Anderson K, et al. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J Vet Intern Med 2007;21:431-439.
17. Lacoste H, Fan TM, de Lorimier LP, et al. Urine N-telopeptide excretion in dogs with appendicular osteosarcoma. J Vet Intern Med 2006;20:335-341.
18. de Lorimier LP, Fan TM. Bone metabolic effects of single-dose zoledronate in healthy dogs. J Vet Intern Med 2005;19: 924-927.
19. Allen MJ, Allen LC, Hoffmann WE, et al. Urinary markers of type I collagen degradation in the dog. Res Vet Sci 2000;69: 123-127.
20. Ladlow JF, Hoffmann WE, Breur GJ, et al. Biological variability in serum and urinary indices of bone formation and resorption in dogs. Calcif Tissue Int 2002;70:186-193.
21. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-1236.
22. Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003;43: 154-162.
23. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-289.
24. Munier A, Gras V, Andrejak M, et al. Zoledronic acid and renal toxicity: Data from French adverse effect reporting database. Ann Pharmacother 2005;39:1194-1197.
25. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679; discussion 1676-1679.
26. McDermott RS, Kloth DD, Wang H, et al. Impact of Zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol 2006;4:524-529.
27. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003;9:2394-2399.
28. Smith MR. Zoledronic acid to prevent skeletal complications in cancer: Corroborating the evidence. Cancer Treat Rev 2005; 31(Suppl 3):19-25.
29. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
30. Goblirsch MJ, Zwolak P, Clohisy DR. Advances in understanding bone cancer pain. J Cell Biochem 2005;96: 682-688.
31. Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61: 4038-4047.
32. Hogler W, Yap F, Little D, et al. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004;145:701-704.
33. Kawada K, Minami H, Okabe K, et al. A multicenter and open label clinical trial of zoledronic acid 4mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 2005;35: 28-33.
34. Sorscher SM. Electrolyte abnormalities with zoledronic acid therapy. Cancer J 2002;8:348; author reply 348-349.